Amy Moore: Are patients with RET+ NSCLC on TKIs protected against cachexia?
Amy Moore, Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation, shared a post on LinkedIn about a recent paper by Ujjwol Khatri et al. published in Cancer Letters:
“This paper is very interesting given my work in the lung cancer and cancer cachexia space.
Are patients with RET+ NSCLC on TKIs protected against cachexia and could these drugs be used to protect those with other forms of oncogene-driven NSCLC (eg EGFR) where weight loss is more common?”
Authors: Ujjwol Khatri, Mohamed Gouda, Shriya Pandey, Neeraj Chauhan, Tao Shen, Xueqing Hu, Min Li, Suming Huang, Vivek Subbiah, Jie Wu.
More posts featuring Amy Moore.
Amy C. Moore is the Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation. She previously served as the Director of Science and Research at the Addario Lung Cancer Medical Institute (ALCMI).
She has published peer-reviewed papers on virology, cancer, and biomarker testing in NSCLC. Dr. Moore is also an expert on COVID-19’s impact on lung cancer and serves on several advisory boards.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023